[Expert advisory on screening and diagnosis of inflammatory risk in coronary artery disease].
Cardiology, C.S.o., Association, C.M., & Cardiology, E.B.o.C.J.o. (2026). [Expert advisory on screening and diagnosis of inflammatory risk in coronary artery disease].. Zhonghua xin xue guan bing za zhi. https://doi.org/10.3760/cma.j.cn112148-20260226-00121
Cardiology CSo, Association CM, Cardiology EBoCJo. [Expert advisory on screening and diagnosis of inflammatory risk in coronary artery disease].. Zhonghua xin xue guan bing za zhi. 2026; doi: 10.3760/cma.j.cn112148-20260226-00121
Cardiology CSo, Association CM, Cardiology EBoCJo. [Expert advisory on screening and diagnosis of inflammatory risk in coronary artery disease].[J]. Zhonghua xin xue guan bing za zhi. 2026. DOI: 10.3760/cma.j.cn112148-20260226-00121.
@article{cardiology2026,
author = {Chinese Society of Cardiology and Chinese Medical Association and Editorial Board of Chinese Journal of Cardiology},
title = {[Expert advisory on screening and diagnosis of inflammatory risk in coronary artery disease].},
journal = {Zhonghua xin xue guan bing za zhi},
year = {2026},
doi = {10.3760/cma.j.cn112148-20260226-00121},
note = {PMID: 42324101},
}
TY - JOUR AU - Chinese Society of Cardiology AU - Chinese Medical Association AU - Editorial Board of Chinese Journal of Cardiology TI - [Expert advisory on screening and diagnosis of inflammatory risk in coronary artery disease]. T2 - Zhonghua xin xue guan bing za zhi PY - 2026 DO - 10.3760/cma.j.cn112148-20260226-00121 AN - PMID:42324101 ER -
冠心病是全球疾病负担最重和导致死亡的主要原因之一，在积极降脂治疗的背景下，炎症风险已被证实为冠心病患者心血管事件的重要预测因素。近年来，随着抗炎治疗临床证据的积累，尤其是秋水仙碱等药物在冠心病二级预防中获益已被确证，炎症管理正逐步成为冠心病综合防治的新方向。在此背景下，中华医学会心血管病学分会心血管免疫与炎症学组联合心血管指南与共识学组、动脉粥样硬化与冠心病学组、中华心血管病杂志编辑委员会，基于最新循证医学证据和中国人群数据，围绕冠心病炎症风险的筛查指标、判定标准、影像学评估及抗炎治疗监测等关键临床问题制定了该专家建议，旨在为我国冠心病患者的炎症风险管理提供规范化指导建议，推动冠心病精准防治体系的建立与完善。.